布洛芬(Ibuprofen) - 药物靶点：COX_在研适应症：动脉导管未闭，慢性疼痛，幼年特发性关节炎_专利_临床

概要

基本信息

简介布洛芬是一种小分子药物，具有 COX 抑制剂的作用。强生公司于 1978 年 8 月批准了该药，主要用于治疗类风湿性关节炎、关节炎、发烧和疼痛等疾病。布洛芬会阻碍产生前列腺素的 COX 酶的活性。这些激素参与炎症和疼痛信号传导。通过减少前列腺素的产生，布洛芬可以减轻炎症并减轻疼痛。多种形式的布洛芬可在柜台购买，包括片剂、胶囊和外用乳膏。虽然布洛芬通常是安全的，但长期使用或高剂量使用会增加胃肠道出血、肾脏损伤和心脏问题等副作用的风险。患者应遵守推荐剂量，如果症状持续或恶化，应寻求医疗建议。

药物类型

小分子化药

别名

(4-isobutylphenyl)-α-methylacetic acid、(RS)-ibuprofen、(±)-2-(p-isobutylphenyl)propionic acid

+ [93]

靶点

COX

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [6]

在研适应症

动脉导管未闭慢性疼痛幼年特发性关节炎+ [25]

非在研适应症

原研机构

在研机构

+ [16]

非在研机构

北京爱力佳医药科技有限公司

Oxford Pharmascience Ltd.

Apsen Farmaceutica S/A

+ [13]

最高研发阶段批准上市

首次获批日期

中国 (1966-01-01),

关节炎发热疼痛

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看首次获批时间轴

结构

分子式C13H18O2

InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N

CAS号15687-27-1

关联

987

项与布洛芬相关的临床试验

NCT06398054 / Not yet recruiting临床4期

Comparison of the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy: a Randomized, Phase iv, Double-blind Trial

For outpatient hysteroscopy (OH), it is recommended to take a standard dose of NSAIDs or more hyoscine-n butyl bromide (HBB) an hour prior to the procedure to minimize pain during the first postoperative hour. As there is currently no clear consensus in the literature regarding the best approach to pain management associated with office hysteroscopy procedures. This Phase 4 study is being conducted to evaluate the effectiveness of oral ibuprofen alone and in combination with HBB to determine the most appropriate strategy for improving pain perception in outpatients.

开始日期2024-10-01

申办/合作机构

ASST Fatebenefratelli Sacco

NCT06539741 / Not yet recruitingN/AIIT

Mechanisms of Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction

Nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, are recommended as first-line treatment for post-surgical dental pain. However, there is variability in analgesic response, and some patients require supplemental opioids for adequate pain relief. The goal of this study is to identify the factors that contribute to the need for opioid after third molar extraction to help limit unnecessary opioid prescriptions in patients who will have good pain relief with ibuprofen alone.

开始日期2024-10-01

申办/合作机构

University of Pennsylvania

[+1]

NCT06496854 / Not yet recruiting临床2期IIT

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

The objective of this pilot study is to discuss the feasibility of prescribing lorazepam prior to IUD insertion and of measuring effect of lorazepam on anxiety and pain with Intrauterine Device (IUD) insertion. The target population for this study will be 25 adult participants scheduled for an IUD insertion at a UW Family Medicine residency clinic. Participants will be followed for 1 appointment visit.

开始日期2024-09-01

申办/合作机构

University of Wisconsin

100 项与布洛芬相关的临床结果

登录后查看更多信息

100 项与布洛芬相关的转化医学

登录后查看更多信息

100 项与布洛芬相关的专利（医药）

登录后查看更多信息

16,454

项与布洛芬相关的文献（医药）

2024-12-31·Renal Failure

Association between postoperative ibuprofen exposure and acute kidney injury after pediatric cardiac surgery

Article

作者: Fang, Zhongrong ; Xiong, Chao ; Shi, Sheng ; Wang, Jianhui ; Bie, Dongyun

BACKGROUNDAcute kidney injury (AKI) is a common complication after pediatric cardiac surgery and is associated with worse outcomes. Ibuprofen is widely used in the perioperative period and can affect kidney function in children. However, the association between ibuprofen exposure and AKI after pediatric cardiac surgery has not been determined yet.METHODSIn this retrospective cohort study, children undergoing cardiac surgery with cardiopulmonary bypass were studied. Exposure was defined as given ibuprofen in the first 7 days after surgery. Postoperative AKI was diagnosed using the KDIGO criteria. A multivariable Cox regression model was used to assess the association between ibuprofen exposure and postoperative AKI by taking ibuprofen as a time-varying covariate.RESULTSAmong 1,112 included children, 198 of them (17.8%) experienced AKI. In total, 396 children (35.6%) were exposed to ibuprofen. AKI occurred less frequently among children who were administered ibuprofen than among those who were not (46 of 396 [11.6%] vs. 152 of 716 [21.2%], p < 0.001). Using the Cox regression model accounting for time-varying exposures, ibuprofen treatment was not associated with AKI (adjusted HR, 0.99; 95% CI 0.70-1.39, p = 0.932). This insignificant association was consistent across the sensitivity and subgroup analyses.CONCLUSIONSPostoperative ibuprofen exposure in pediatric patients undergoing cardiac surgery was not associated with an increased risk of AKI.

2024-12-31·Journal of Obstetrics and Gynaecology

Ge-gen decoction alleviates primary dysmenorrhoea symptoms in a rat model

Article

作者: Gu, Zhijuan ; Xu, Haifeng ; Xie, Yazhen

BACKGROUNDExisting treatments for primary dysmenorrhoea (PD), such as NSAIDs, impart side effects. Ge-Gen decoction (GGD), a traditional Chinese medicine, has shown promise in treating PD, but its exact mechanisms remain unclear. Here, we aimed to investigate the efficiency of GGD in alleviating PD using a rat model to understand its precise mechanism of action.METHODSWe established a rat model of dysmenorrhoea induced by oestradiol and oxytocin. The PD rats were administered GGD or Ibuprofen (positive control) intragastrically once daily for seven consecutive days. Serum levels of prostaglandin E2 (PGE2), prostaglandin F2 alpha (PGF2α), β-endorphin (β-EP), thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-keto-PGF1α) were determined using an enzyme-linked immunosorbent assay (ELISA). The expression levels of oestrogen receptor alpha (ERα) and cyclooxygenase-2 (COX-2) in uterine tissue were measured using immunohistochemical assays, and those of phosphorylated and total extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) were assessed using western blot analysis.RESULTSTreatment with GGD significantly reduced writhing behaviour, histopathological scores, and levels of COX-2, PGE2, and PGF2α in the serum of PD rats. Additionally, GGD increased β-EP content and inhibited ERK1/2 activation and ERα expression in uterine tissues.CONCLUSIONSThe results of this study suggest that GGD alleviates PD in rats by suppressing the COX-2-mediated release of PGE2 and PGF2α, modulating the ERα/ERK1/2/COX-2 pathway, and increasing β-EP content. These results provide insights into the potential mechanisms of GGD in treating PD and support its further investigation as an alternative therapy for this condition.

2024-12-31·Annals of Medicine

Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis

Review

作者: Tian, Jinhui ; Xie, Runsheng ; Li, Jiahui ; Jing, Yuyu ; Xu, Feilong ; Cai, Yefeng ; Li, Hui ; Wang, Yangyang ; Chen, Wenjia

OBJECTIVETension-type headache is the most common type of primary headache and results in a huge socioeconomic burden. This network meta-analysis (NMA) aimed to compare the efficacy and safety of simple analgesics for the treatment of episodic tension-type headache (ETTH) in adults.METHODSWe searched the Cochrane Library, PubMed, Web of Science, Embase, Chinese BioMedical Literature database and International Clinical Trials Registry Platform databases for eligible randomized clinical trials reporting the efficacy and/or safety of simple analgesics. A Bayesian NMA was performed to compare relative efficacy and safety. The surface under the cumulative ranking curve (SUCRA) was calculated to rank interventions. PROSPERO registration number: CRD42018090554.RESULTSWe highlighted six studies including 3507 patients. For the 2 h pain-free rate, the SUCRA ranking was ibuprofen > diclofenac-K > ketoprofen > acetaminophen > naproxen > placebo. All drugs except naproxen reported a higher 2 h pain-free rate than placebo, with a risk ratio (RR) of 2.86 (95% credible interval, CrI: 1.62-5.42) for ibuprofen and 2.61 (1.53-4.88) for diclofenac-K. For adverse events rate, the SUCRA ranking was: metamizol > diclofenac-K > ibuprofen > lumiracoxib > placebo > aspirin > acetaminophen > naproxen > ketoprofen. The adverse event rates of all analgesics were no higher than those of placebo, except for ketoprofen. Moreover, all drugs were superior to placebo in the global assessment of efficacy. In particular, the RR of lumiracoxib was 2.47 (1.57-4.57). Global heterogeneity I² between the studies was low.CONCLUSIONSSimple analgesics are considered more effective and safe as a placebo for ETTH in adults. Our results suggest that ibuprofen and diclofenac-K may be the two best treatment options for patients with ETTH from a comprehensive point of view (both high-quality evidence).

619

项与布洛芬相关的新闻（医药）

2024-09-02

·Pharma CMC

刚刚，79个新批件，一款罕见病药物获批上市！

刚刚，NMPA发布2024年09月02日药品批准证明文件送达信息，本批次共有79个受理号获批，其中59个为上市申请受理号，获批品种包括：江苏正大清江制药的磷酸奥司他韦干混悬剂；齐鲁制药、昆山龙灯瑞迪制药的达格列净片；平光制药的己酮可可碱注射液；贵州益佰制药的普乐沙福注射液；北京诚济制药的布洛芬混悬液；北京福元医药的丙戊酸钠缓释片（I）等。此外，杰谛医药引进的盐酸曲恩汀胶囊获批上市，用于治疗对不能耐受青霉胺的肝豆状核变性（又称Wilson病）成人及儿童患者。据公开资料显示，盐酸曲恩汀胶囊是一款铜离子络合剂，作用类似青霉胺，可以促使铜通过肾脏排出体外。该药最早由德国默克开发，1985年在美国获批上市，用于治疗威尔逊病，可供不能耐受青霉胺的患者选用。原研药至今未在国内上市。 2023年3月，杰谛医药递交5.2类化药盐酸曲恩汀胶囊的上市申请，后续其上市申请被纳入优先审评。

上市批准优先审批

2024-08-29

·Endpoints

Afrigen, CEPI to speed up mRNA vaccine manufacturing; Bora Pharma invests in Tanvex

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. The Coalition for Epidemic Preparedness Innovations (CEPI) is partnering with and funding a research project for Afrigen Biologics to investigate if the use of synthetic DNA can speed up mRNA vaccine development. The synthetic DNA will be manufactured and supplied by the CDMO Syngoi. The research project will develop a vaccine for Rift Valley fever, according to a Tuesday press release. Bora Pharmaceuticals is gaining a 30.5% share in Tanvex Biopharma in a new partnership that will combine their manufacturing services. Bora will provide its 10 global manufacturing sites and Tanvex will provide its commercial facility in San Diego, CA. No financial details were given. Bharat Biotech is launching an oral cholera vaccine, dubbed Hillchol, to address cholera vaccine shortages. The company will manufacture this out of its facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses, the company said on Tuesday. John Kosolcharoen, CEO of two stem cell manufacturing companies, pleaded guilty on Monday for marketing products linked to patient hospitalizations. Since 2016, the two companies, called Liveyon LLC and Genetech Inc. have been making and shipping unapproved injectable stem cell products manufactured from human umbilical cord blood. Kosolcharoen lied to the FDA stating these were being sold for research purposes only, as per a DOJ press release on Tuesday. AstraZeneca’s manufacturing facility in Södertälje, Sweden, has achieved a 98% reduction in greenhouse gas emissions since 2015, the company said on Thursday. ScaleReady has awarded a $20 million grant to Stanford Medicine Laboratory for Cell and Gene Medicine to help the development of its CAR-T cell therapy manufacturing platform. The funding will be used to investigate the manufacturing tech in a Phase 1 clinical trial for Glypican 2 pediatric neuroblastoma and medulloblastoma, the company said on Tuesday. Trinity Capital is investing $35 million into drug delivery device manufacturer ApiJect Systems. The funding will be used to expand ApiJect’s manufacturing footprint with a new facility, according to a press release on Tuesday. Molecular Assemblies has received $4 million in funding from the Defense Advanced Research Projects Agency (DARPA) to further develop its DNA synthetic technology. The funding will be used for future tech transfers and to develop other software like gene synthesis, the company said on Wednesday. Injectable CDMO Simtra Biopharma Solutions has tapped Lonza’s VP of Biologics, Lidia Serina, as its new head of development services. Prior to working at Lonza, Serina held positions at GSK, Sanofi and CureVac. CDMO Huateng Pharma is expanding its services to include manufacturing pharmaceutical and veterinary APIs, chemicals and cosmetic ingredients, according to a press release on Wednesday. Lupin Pharmaceuticals is voluntarily recalling 4554 bottles of its cefixime oral suspension from the US due to an out-of-specification result. The class 2 recall started on Aug. 21, according to a FDA report published on Monday. Dr. Reddy’s Laboratories is also voluntarily recalling 103,298 bottles of 800 mg ibuprofen tablets after a specification study showed some levels of impurities. The bottles are being recalled from the US and Puerto Rico, and the process is ongoing. The FDA classified this as a class 2-level recall.

临床1期疫苗

2024-08-27

·米内网

【瞩目】葫芦娃药业发威！12个重磅产品获批，33个新品冲刺上市，3款新药猛攻儿童药市场

精彩内容今年以来，葫芦娃药业新品研发喜讯不断，刚过去的7月，公司的富马酸丙酚替诺福韦片和布洛芬混悬滴剂获批上市并视同过评。目前葫芦娃药业及子公司共有1个中药经典名方、32个高端仿制药冲刺上市，有望在四大品类市场迎来新突破。作为儿童药明星企业，葫芦娃药业的新药研发也紧盯儿童药市场，3款新药正在火速推进，未来可期。 12个重磅新品获批，两个百亿市场大突破葫芦娃药业长期以来聚焦儿童药领域，产品类别涵盖特色中药、化学药等，已构建起以儿童药为主，与成人药相结合的产品规划，围绕儿童的呼吸系统、消化系统、抗感染类和其他药物进行布局。米内网数据显示，近两年公司的新品获批迎来爆发期：2023年共拿下3个新品，涉及呼吸系统用药、神经系统药物、心脑血管系统药物；2024年至今已有9个新品获批，涉及肌肉-骨骼系统（2个）、全身用抗感染药物（3个）、呼吸系统用药（4个）。表1：2023年至今葫芦娃药业及子公司获批的新产品来源：米内网中国申报进度（MED）数据库 2023年11月，公司的缬沙坦氨氯地平片(Ⅰ)获批上市并视同过评，该产品用于治疗原发性高血压以及用于单药治疗不能充分控制血压的患者，该产品是葫芦娃药业首款获批的高血压用药。2023年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端（化学药+生物药）市场，高血压用药的市场规模在470亿元以上，葫芦娃药业成功撬开了这个百亿市场大门。 2024年4月，公司的硫酸特布他林雾化吸入用溶液获批上市并视同过评，该产品用于缓解支气管哮喘、慢性支气管炎、肺气肿及其它肺部疾病所合并的支气管痉挛，适用人群包括成人及儿童。2023年在中国公立医疗机构终端（化学药+生物药）市场，吸入剂的市场规模在240亿元以上，硫酸特布他林雾化吸入用溶液是葫芦娃药业首款获批的吸入剂。表2：葫芦娃药业已过评/视同过评产品情况来源：米内网中国申报进度（MED）数据库 2021年11月，葫芦娃药业的注射用阿奇霉素和注射用奥美拉唑钠过评，成为公司第一批过评的产品，具有积极意义，截至2024年8月27日，葫芦娃药业及子公司共有20个产品过评/视同过评。有了充足的产品储备，葫芦娃药业也积极参与国家集中带量采购，在2023年举办的第八批、第九批国采中，公司分别中标了注射用头孢西丁钠（供应省份：吉林、上海、云南）、盐酸托莫西汀口服溶液（主供省份：江西、四川、甘肃、青海；备供省份：山东、陕西、天津、吉林）。值得注意的是，公司的盐酸托莫西汀口服溶液是2023年获批的新产品，“光脚产品”借助国采之力有望实现销售大放量，成绩值得期待。目前，公司过评且暂未纳入国采的产品中，帕拉米韦注射液、布洛芬混悬液、地氯雷他定口服溶液3个产品的竞争企业（原研+过评）≥5家，若能进入第十批国采目录且顺利中标，葫芦娃药业这3个按新分类获批的“光脚产品”有望迎来新一轮爆发期，对公司业绩有提振作用。首款中药经典名方备受瞩目，32个仿制药新品在路上葫芦娃药业正在积极开发稳定性更好、顺应性更强的吸入制剂、口溶膜剂等技术壁垒高、市场前景广的新剂型儿科产品，开发速释、缓释、控释等高端新药制剂，瞄准国际高端新药研发和市场方向，为国内病患提供更优质、更前沿的创新产品。米内网数据显示，2023年至今，葫芦娃药业及子公司有1个中药新药、32个化药仿制药报产在审，涉及10个大类（23个亚类）。表3：2023年至今葫芦娃药业及子公司报产在审的新产品来源：米内网中国申报进度（MED）数据库易黄颗粒是葫芦娃药业首款申报上市的中成药3.1类新药（即按古代经典名方目录管理的中药复方制剂）。资料显示，易黄汤为固涩剂，具有固肾止带，清热祛湿之功效，主治肾虚湿热带下，带下粘稠量多，色黄如浓茶汁，其气腥秽，舌红，苔黄腻者，临床常用于治疗宫颈炎、阴道炎等属肾虚湿热下注者。该新药目前仅有葫芦娃药业报产在审，大概率能拿下国产首家。此外，枸橼酸托法替布口服溶液、维生素K滴剂、头孢托仑匹酯颗粒目前均未有国内药企获得生产批文，葫芦娃药业将参与3个产品的国内首仿争夺，值得期待。目前公司暂无治疗便秘的化药、造影剂、免疫抑制剂、影响骨结构及其矿化的化药获批，乳果糖口服溶液、钆布醇注射液、枸橼酸托法替布口服溶液、注射用唑来膦酸浓溶液或将为公司开辟4个新市场。儿童药新药加速推进，中成药+化药双布局目前，我国儿童用药配备不足，呈现“三少两多”的市场特点，即儿童专用药品种少、剂型少、剂量规格少、普药多、不良反应情况多等情况。近几年国家对儿童用药关注度不断提升，各种鼓励儿童药研发的政策陆续出台，我国儿童药市场将迎来更广阔的发展前景。葫芦娃药业表示，随着各项政策的落地，公司在儿童药领域的布局将进一步深入，尤其是在研发方面，将集中优势资源加快儿药项目的研发进程，更好的为广大儿童的健康做好服务。目前公司有两款中药新药和1款化药改良新药进展较快，均属于儿童药。表4：葫芦娃药业及子公司在研的儿童新药来源：米内网中国临床试验数据库小儿化积颗粒用于小儿脾胃不和，停食停乳，积聚痞块，肚腹膨胀，四肢倦怠，面色萎黄，不思饮食等症。公司在2018年获得临床批件，目前已在III期临床阶段，上市可期。小儿麻龙止咳平喘颗粒适用于素有风痰，郁而化热，痰热互结，肺失宣肃，气机上逆而致的反复咳嗽，夜间或晨起尤甚，伴痰粘难咯等症状者。公司在2018年获得临床批件，目前已完成II期临床。 LPC-006口溶膜是公司在2023年获批临床的化药改良新药，用于治疗抗癫痫病，属于二类精神药物。该新药是公司首款申报的口溶膜，为公司进军高技术壁垒药物市场奠定基础。资料来源：米内网数据库、公司公告等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至8月27日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

上市批准带量采购

100 项与布洛芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00126	布洛芬	M02AA13 R02AX02 M01AE01 G02CC01 C01EB16	DB01050

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
动脉导管未闭	冰岛	Recordati Rare Diseases, Inc.	2004-07-28
动脉导管未闭	列支敦士登	Recordati Rare Diseases, Inc.	2004-07-28
动脉导管未闭	挪威	Recordati Rare Diseases, Inc.	2004-07-28
动脉导管未闭	欧盟	Recordati Rare Diseases, Inc.	2004-07-28
慢性疼痛	澳大利亚	Viatris Pty Ltd.	2001-11-12
幼年特发性关节炎	澳大利亚	Viatris Pty Ltd.	2001-11-12
骨关节炎	澳大利亚	Viatris Pty Ltd.	2001-11-12
原发性痛经	澳大利亚	Viatris Pty Ltd.	2001-11-12
炎症	日本	Kaken Pharmaceutical Co., Ltd.	1971-06-25
类风湿关节炎	英国	Johnson & Johnson	1969-01-01
关节炎	中国	丹东医创药业有限责任公司	1966-01-01
发热	中国	丹东医创药业有限责任公司	1966-01-01
疼痛	中国	丹东医创药业有限责任公司	1966-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
发热	临床3期	澳大利亚	Cumberland Pharmaceuticals, Inc.	2002-06-01
骨关节炎	临床3期	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19
疼痛	临床3期	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19
疼痛	临床1期	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19
发热	临床前	澳大利亚	Cumberland Pharmaceuticals, Inc.	2002-06-01
疼痛	临床前	美国	McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.	1974-09-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03929640 (CTgov)	临床3期	术后疼痛	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	(餘夢壓積獵選餘衊鹽範) = 網廠繭鏇鑰衊積簾淵壓衊鑰糧醖構顧鑰築製顧 (窪窪積鏇鑰選糧顧網製, 簾願齋觸遞齋觸鹹選鹹 ~ 窪鑰淵繭範憲蓋顧膚襯) 更多	-	2024-09-04
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	(餘夢壓積獵選餘衊鹽範) = 製衊簾襯遞鑰蓋衊築遞衊鑰糧醖構顧鑰築製顧 (窪窪積鏇鑰選糧顧網製, 鏇膚獵襯築廠觸積齋獵 ~ 顧鑰壓獵襯鹽顧鹽齋獵) 更多
NCT04791761 (CTgov)	临床1/2期	术后疼痛	73	Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone (Opioid Pain Control)	鹽構願積繭糧夢鏇鹽蓋(鏇顧艱壓遞鑰築淵範願) = 觸醖願糧鬱鏇觸觸憲鑰憲範醖簾製網鹹鬱觸艱 (鹽艱網繭築選醖糧範蓋, 範襯鹹齋遞範膚膚顧襯 ~ 繭網鬱獵齋淵襯願夢觸) 更多	-	2024-08-16
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	鹽構願積繭糧夢鏇鹽蓋(鏇顧艱壓遞鑰築淵範願) = 廠願鏇積簾鹹壓窪夢壓憲範醖簾製網鹹鬱觸艱 (鹽艱網繭築選醖糧範蓋, 鑰膚艱艱襯製襯衊淵鏇 ~ 糧製淵選願積壓憲夢蓋) 更多
NCT03399318 (Pubmed)	临床3期	-	256	Aggressive antipyretic therapy (acetaminophen + ibuprofen)	構鹹餘鏇廠廠鑰糧餘憲(膚製積願選夢鹹遞餘鑰) = 壓醖餘鹽衊願獵顧蓋鬱襯鏇積製遞鹽觸醖艱遞 (淵蓋積淵艱範夢夢餘築, -0.62) 更多	积极	2024-06-10
				Usual care (acetaminophen alone)	構鹹餘鏇廠廠鑰糧餘憲(膚製積願選夢鹹遞餘鑰) = 範鏇網膚窪壓襯糧鬱廠襯鏇積製遞鹽觸醖艱遞 (淵蓋積淵艱範夢夢餘築, -0.82 ~ -0.42) 更多
NCT03785756 (CTgov)	临床3期	疼痛	280	Placebo of IR tablet+Ibuprofen 300 mg Oral Tablet (Prolonged Release Group)	觸願襯簾製糧範獵齋構(選衊糧醖淵構觸鏇願觸) = 廠觸膚衊齋鹹憲襯廠艱簾簾襯艱鏇繭糧築齋廠 (顧願糧蓋積艱廠製艱餘, 獵選廠獵構餘廠醖廠鹽 ~ 餘蓋夢餘憲積鹽艱鹹壓) 更多	-	2024-06-03
				Placebo of IR tablet+Ibuprofen 200 mg Oral Tablet (Immediate Release Group)	觸願襯簾製糧範獵齋構(選衊糧醖淵構觸鏇願觸) = 糧鹽鹹觸艱積範膚網餘簾簾襯艱鏇繭糧築齋廠 (顧願糧蓋積艱廠製艱餘, 遞餘蓋獵衊範憲廠願獵 ~ 淵遞夢淵廠衊窪艱醖築) 更多
NCT02929589 (CTgov)	临床3期	疝 \| 术后疼痛	18	ibuprofen (Opioid naïve Patients-Group A)	壓膚鑰餘鹽鑰鏇夢艱簾(選蓋鹹選鏇網鑰蓋衊範) = 鑰範蓋艱積顧鏇襯廠艱艱醖鏇襯選齋蓋網簾糧 (觸衊獵觸餘積餘範鏇窪, 遞積淵艱網齋顧鬱膚鬱 ~ 憲鬱鑰膚憲衊鏇齋廠糧) 更多	-	2024-03-26
				Opioid medication+Ibuprofen (Non-Opioid naïve Patients-Group C)	衊艱壓膚觸鬱觸選選觸(鹽夢鬱壓醖醖製選鑰糧) = 構蓋構觸醖觸淵膚構築鏇餘夢網夢網憲齋網憲 (夢鏇憲鬱鹽觸範製鬱鏇, 淵鑰選醖蓋餘廠窪顧鹹 ~ 鏇繭憲蓋壓製顧醖繭構) 更多
NCT04905563 (CTgov)	临床4期	肱骨骨折 \| 术后疼痛	30	Acetaminophen-Hydrocodone (Control)	(鹽艱糧夢繭夢顧糧選艱) = 鏇鑰衊積鏇窪糧衊憲蓋鹽艱選繭網醖製艱築遞 (餘衊醖壓襯廠衊齋簾遞, 鑰廠觸壓鏇壓壓選齋鏇 ~ 獵窪蓋淵蓋壓廠簾夢鹽) 更多	-	2024-03-08
				Acetaminophen+Ibuprofen (Treatment)	(鹽艱糧夢繭夢顧糧選艱) = 憲餘淵憲齋鬱簾蓋觸蓋鹽艱選繭網醖製艱築遞 (餘衊醖壓襯廠衊齋簾遞, 淵醖憲蓋醖遞夢顧蓋夢 ~ 築網糧夢憲夢糧獵鏇醖) 更多
NCT03399318 (CTgov)	临床2期	脑型疟疾 \| 癫痫发作 \| 虫血症 \| 中暑 \| 昏迷 \| 发热	256	placebo+acetaminophen+ibuprofen (Aggressive Antipyretics (AA))	窪夢艱壓遞簾衊構選構(願獵顧衊積蓋製憲構構) = 鏇築鬱鏇鹹鏇蓋構淵觸憲鹽網觸構蓋選壓淵製 (選醖積築繭網鹽廠鏇鬱, 壓窪醖憲選選夢衊遞淵 ~ 築夢製鏇夢衊廠齋範鹹) 更多	-	2024-03-05
				acetaminophen+ibuprofen (Usual Care (UC).)	窪夢艱壓遞簾衊構選構(願獵顧衊積蓋製憲構構) = 衊淵衊繭製簾選衊蓋醖憲鹽網觸構蓋選壓淵製 (選醖積築繭網鹽廠鏇鬱, 壓膚糧蓋簾製夢繭鏇築 ~ 範簾積窪範範積膚鏇襯) 更多
NCT03011567 (HIPPS, CTgov)	N/A	先兆子痫	202	Ibuprofen (Severe HDP- NSAID)	醖淵艱醖構鹽網簾衊繭(築鬱繭鑰淵蓋夢網糧壓) = 觸網網積醖夢構願鏇蓋廠鬱艱鹽網醖繭蓋築築 (淵廠構鏇網繭蓋壓鏇衊, 遞選衊構壓蓋鹹範艱艱 ~ 淵齋遞餘鬱壓鏇鬱繭遞) 更多	-	2024-01-03
				Ibuprofen (Mild HDP- NSAID)	醖淵艱醖構鹽網簾衊繭(築鬱繭鑰淵蓋夢網糧壓) = 構獵遞積積築襯憲構鑰廠鬱艱鹽網醖繭蓋築築 (淵廠構鏇網繭蓋壓鏇衊, 顧廠憲壓繭願醖網積築 ~ 獵簾鏇範醖願窪鏇餘願) 更多
NCT05544734 (CTgov)	临床4期	镇痛 \| 指甲畸形 \| 指甲疾病	20	Hydrocodone 5Mg/Acetaminophen 325Mg Tab+Acetaminophen 1000mg+Ibuprofen 400 mg (Hydrocodone 5mg/Acetaminophen 325mg)	襯鹽衊鬱餘積製製構簾(顧齋夢艱遞築獵簾醖獵) = 繭衊壓簾蓋衊鹹築壓艱繭製網蓋鬱製選繭餘鬱 (範鏇築襯鑰繭願繭遞餘, 襯齋衊鏇築簾糧範壓壓 ~ 觸衊簾鬱艱築膚築糧製) 更多	-	2023-09-28
				Acetaminophen 1000mg+Ibuprofen 400 mg (Acetaminophen 1000mg + Ibuprofen 400mg)	襯鹽衊鬱餘積製製構簾(顧齋夢艱遞築獵簾醖獵) = 艱齋願製蓋醖醖鏇築襯繭製網蓋鬱製選繭餘鬱 (範鏇築襯鑰繭願繭遞餘, 糧淵鹹選鏇範製觸構積 ~ 簾遞選繭製糧繭醖醖憲) 更多